Habib Shahid
Department of Hepatology, Liver Institute PLLC, Tucson, AZ 85716, United States.
World J Gastrointest Pathophysiol. 2024 May 24;15(2):92791. doi: 10.4291/wjgp.v15.i2.92791.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a widespread global disease with significant health burden. Unhealthy lifestyle, obesity, diabetes mellitus (DM), insulin resistance, and genetics have been implicated in the pathogenesis of MASLD. A significant degree of heterogeneity exists among each of above-mentioned risk factors. Heterogeneity of these risk factors translates into the heterogeneity of MASLD. On the other hand, MASLD can itself lead to insulin resistance and DM. Such heterogeneity makes it difficult to assess the natural course of an individual with MASLD in clinical practice. At present MASLD is considered as one disease despite the variability of etiopathogenic processes, and we lack the consensus definitions of unique subtypes of MASLD. In this review, pathogenic processes of MASLD are discussed and a need of subtyping is recommended.
代谢功能障碍相关脂肪性肝病(MASLD)是一种全球性广泛存在的疾病,具有重大的健康负担。不健康的生活方式、肥胖、糖尿病(DM)、胰岛素抵抗和遗传因素都与MASLD的发病机制有关。上述每个风险因素之间都存在显著程度的异质性。这些风险因素的异质性导致了MASLD的异质性。另一方面,MASLD本身可导致胰岛素抵抗和糖尿病。这种异质性使得在临床实践中难以评估个体MASLD的自然病程。目前,尽管MASLD的病因发病过程存在变异性,但仍被视为一种疾病,并且我们缺乏MASLD独特亚型的共识定义。在本综述中,我们讨论了MASLD的发病过程,并建议进行亚型分类。